Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Tumor anemia and thrombocytosis in patients with vulvar cancer
Autore:
Hefler, L; Mayerhofer, K; Leibman, B; Obermair, A; Reinthaller, A; Kainz, C; Tempfer, C;
Indirizzi:
Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 tet & Gynecol, Houston, TX 77030 USA Univ Vienna, Sch Med, Dept Gynecol & Obstet, Vienna, Austria Univ Vienna Vienna Austria Med, Dept Gynecol & Obstet, Vienna, Austria
Titolo Testata:
TUMOR BIOLOGY
fascicolo: 5, volume: 21, anno: 2000,
pagine: 309 - 314
SICI:
1010-4283(200009/10)21:5<309:TAATIP>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROGNOSTIC FACTORS; CERVICAL-CANCER; CARCINOMA; SURVIVAL; WOMEN;
Keywords:
anemia; thrombocytosis; vulvar cancer; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Hefler, L Baylor Coll Med, Dept Obstet & Gynecol, Smith Tower,6550 Fannin Suite 901,Houston, TX 77030 USA Baylor Coll Med Smith Tower,6550 Fannin Suite 901 Houston TX USA 77030
Citazione:
L. Hefler et al., "Tumor anemia and thrombocytosis in patients with vulvar cancer", TUMOR BIOL, 21(5), 2000, pp. 309-314

Abstract

The aim of our study was to determine the prevalence of tumor anemia and thrombocytosis in patients with vulvar cancer, and to evaluate the prognostic value or pretreatment hemoglobin (Hb) and platelet count regarding disease-free and overall survival of patients with vulvar cancer. We measured pretreatment Hb and platelet count in 62 patients with squamous cell vulvar cancer. The results were correlated to clinical data. Median Hb and platelet count in patients with vulvar cancer were 13.1 g/dl (range 8.3-16.2) and 268,500/mu l (range 88,000-778,000), respectively. Cut-off levels of 12 g/dl and 300,000/mu l were selected for tumor anemia and tumor thrombocytosis, respectively according to published criteria. Tumor anemia and tumor thrombocytosis were present in 30.6 and 27.4% of patients with vulvar cancer, respectively. In a univariate analysis tumor stage and tumor thrombocytosis were significantly associated with a shortened disease-free (log-rank test, p < 0.001 and p = 0.003, respectively) and overall survival (log-rank test, p< 0.001 and p < 0.001, respectively). Tumor anemia was not associated witha shortened disease-free, but with a shortened overall survival of patients with vulvar cancer (log-rank test, p = 0.1 and p = 0.002, respectively). A multivariate Cox regression model considering tumor stage, tumor anemia, and tumor thrombocytosis showed, however, that pretreatment Hb and plateletcount did not confer additional prognostic information to that already obtained by the established prognosticator tumor stage on disease free (multivariate Cox regression model, p = 0.8, p = 0.2, and p = 0.003, respectively)and overall survival (multivariate Cox regression model, p = 0.4, p = 0.5,and p = 0.04, respectively). Pretreatment tumor anemia and tumor thrombocytosis were associated with a poor prognosis, but were not an independent predictor of outcome in patients with vulvar cancer. Copyright (C) 2000 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 19:38:46